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Abstract
AIM
To investigate beta-blocker (BB) use in patients with 
cirrhosis and determine their effects on physical frailty 
and overall survival.
METHODS
Adult outpatients with cirrhosis listed for liver trans-
plantation underwent testing of physical frailty using 
the performance-based Liver Frailty Index, comprised of 
chair stands, grip strength, and balance testing, as well 
as self-reported assessments of exhaustion and physical 
activity. BB use was assessed from medical chart review. 
Univariable and multivariable logistic regression were 
performed to determine BB use and their association 
with measures of physical frailty. Competing risk 
analyses were performed to determine the effect of 
BB use on wait-list mortality, as defined by death or 
delisting for being too sick for transplant.
RESULTS
Of 344 patients, 35% were female, median age was 60, 
median model for end stage liver disease was 15, and 
53% were prescribed a BB. Compared to those not on 
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BB, patients on BB were similar except for percentage 
female (25% vs  46%; P  < 0.001) and BMI (29 vs  28; 
P  = 0.008). With respect to tests of physical frailty, BB 
use was not associated with increased odds of frailty 
(by the Liver Frailty Index), exhaustion, or low physical 
activity. BB use was, however, significantly associated 
with a decreased adjusted risk of mortality (SHR 0.55; 
P  = 0.005).
CONCLUSION
In patients with cirrhosis awaiting liver transplantation, 
BB use is not associated with physical frailty. We 
confirmed the known survival benefits with BB use, and 
concerns about adverse effects should not deter their 
utilization when indicated.
Key words: Beta-blockers; Cirrhosis; End-stage liver 
disease; Frailty 
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: In patients with cirrhosis, beta-blockers are 
the main medical treatment for prevention of variceal 
bleeds, but fatigue and weakness are commonly 
reported side effects. This study demonstrates that use 
of beta-blockers is not associated with physical frailty 
and improves survival in patients with cirrhosis.
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physical frailty in patients with end-stage liver disease. World J 
Gastroenterol 2018; 24(33): 3770-3775  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v24/i33/3770.htm  DOI: 
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INTRODUCTION
Physical frailty is reported to be prevalent in patients 
with cirrhosis and has emerged as a critical determinant 
of outcomes in this population[1-3]. Resulting from the 
loss of homeostatic balance of multiple physiologic 
systems including (but not limited to) musculoskeletal, 
inflammatory, endocrine, and neurocognitive, physical 
frailty has been operationalized using standardized 
instruments that measure multiple domains such as 
fatigue, weakness, slowness, weight loss, and low 
activity[4]. Two of these physical frailty components, 
fatigue and weakness, overlap with the frequent side 
effects of non-selective beta-blockers (BBs).  
This overlap is of particular importance for patients 
with cirrhosis. Beta-blockers are the main pharmacologic 
therapy for both primary and secondary prevention of 
variceal hemorrhage in patients with cirrhosis[5]. Despite 
the proven clinical effectiveness and known mortality 
benefits of beta-blockers, there is mounting evidence 
that patients are not receiving these treatments due to 
physicians under prescribing, suboptimal adherence, 
and side effects. More recently, investigators have 
hypothesized that a “therapeutic window” exists during 
which a patient with cirrhosis might benefit from beta-
blocker therapy for variceal prevention, with a patient 
losing benefit once they develop refractory ascites[6,7]. 
One study showed that as few as 6%-22% of patients 
with known medium or large varices received primary 
prophylaxis with beta-blockers[8]. Furthermore, concern 
regarding side effects led to discontinuation of beta-
blockers in about 15% of patients with cirrhosis[9]. 
Reluctance to prescribe beta-blocker therapy may 
arise from concerns about their commonly reported 
symptoms of weakness and fatigue[10,11]. Most of the 
studies of beta-blocker side effects are performed 
within the cardiac population, but little is known of their 
effects in patients with cirrhosis. The adverse effects of 
weakness and fatigue, factors that are integral to the 
frail phenotype[4], are of particular importance in this 
population given the recent studies indicating physical 
frailty as a predictor of mortality in patients awaiting 
liver transplant[2,3]. Therefore, in this study, we aimed to 
evaluate the association between beta-blocker use and 
physical frailty in patients with cirrhosis.
MATERIALS AND METHODS
Study population
The Functional Assessment in Liver Transplantation 
(FrAILT) study is an ongoing prospective study of adult 
patients (≥ 18 years) with cirrhosis actively listed for 
liver transplantation and seen as outpatients at the 
University of California, San Francisco (UCSF). This 
retrospective study included data from patients enrolled 
in the FrAILT study from July 2012 until January 2014. 
Included were patients with model for end stage liver 
disease (MELD) score ≥ 12 and excluded were patients 
with severe hepatic encephalopathy, defined by the 
time to complete the Numbers Connection Test of > 
120 s. All participants gave informed consent and the 
UCSF Institutional Review Board approved this study. 
Study procedures and data collection
At enrollment and subsequent clinic visits, all patients 
underwent tests of physical frailty in the outpatient 
clinic setting: (1) the Liver Frailty Index (LFI), consisting 
of chair stands, grip strength, and balance (calculator 
available at https://liverfrailtyindex.ucsf.edu)[1]; (2) 
exhaustion, determined by self-report using two 
questions from the Center for Epidemiological Studies-
Depression scale that have been included in the 
Fried Frailty Phenotype[4]; and (3) physical activity, 
determined by self-report using the Minnesota Leisure 
Time Physical Activity Scale (MNLTPA) that has also 
been included in the Fried Frailty Phenotype[4]. 
Patient demographics, medical co-morbidities, 
degree of ascites, vital signs, beta-blocker use and 
beta-blocker indications were collected from the clinic 
visit note from the same date of their physical frailty 
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assessment. Hepatic encephalopathy (HE) was defined 
as moderate if the patient’s Numbers Connection Test 
score was > 60 s and mild/none if < 60 s. Laboratory 
studies within 3 mo of the study visit were collected 
from the patient’s electronic health record. 
Statistical analysis
Patients were classified as “frail” if they had an LFI score 
of ≥ 4.5, as these cutoffs have been associated with 
worse outcomes in patients awaiting liver transplant[1]. 
Patients were classified as “robust” if they had an LFI 
score of < 3.2[1]. Frailty by the MNLTPA activity level 
was defined as < 383 Kcals/wk for males and < 270 
Kcals/wk for females[4].
Differences in baseline characteristics between beta-
blocker users vs non-users were compared using chi-
square or Wilcoxon ranksum tests for categorical and 
continuous variables, respectively. Differences in heart 
rate, performance measures of physical frailty, and 
self-reported physical frailty were also compared by 
chi-square and Wilcoxon ranksum tests. Univariable 
logistic regression was performed to determine 
associations between beta-blocker use and physical 
frailty. Multivariable models initially included heart rate, 
age, MELD, creatinine, albumin, sodium, presence of 
hepatocellular carcinoma (HCC), degree of ascites, 
and presence of hepatic encephalopathy. All variables 
associated with a P-value < 0.2 in the univariable 
analysis were included in the multivariable model and a 
backwards stepwise selection was used to only include 
variables with a P < 0.05.
Competing risk analysis evaluated the effect of beta-
blocker use on wait-list mortality, as defined by death 
or delisting for being too sick for transplant, with liver 
transplant as a competing risk. Patients were censored 
at the time of waitlist removal if removed for “other” 
reasons (e.g., violation of substance abuse contract, 
inadequate social support). All variables associated 
with a P-value < 0.2 in the univariate analysis were 
included in the multivariate model and a backward 
stepwise selection was used to eliminate covariates 
using a threshold P-value < 0.05 to determine the 
subdistribution hazard ratio (SHR).
All statistical analyses were performed using STATA® 
version 11 (College Station, TX, United States). The 
statistical methods of this study were reviewed by Lai 
JC, MD, from UCSF who is trained in advanced clinical 
research methodologies. 
RESULTS
Baseline characteristics of the cohort
A total of 344 patients with end-stage liver disease were 
included in this study. Baseline characteristics are listed 
in Table 1, column A. The median (IQR) age was 60 
years (54-64) and 35% were female. The etiology of 
underlying liver disease was hepatitis C in 50%, alcoholic 
liver disease in 15%, nonalcoholic steatohepatitis in 13%, 
autoimmune/cholestatic liver disease in 11%, hepatitis B 
in 4% and “other” in 6%. Median weight and body mass 
index (BMI) were 83.5 kg and 28.4 kg/m2, respectively. 
With respect to medical co-morbidities, 44% had 
hypertension, 32% had diabetes, and 7% had coronary 
artery disease. Hepatic encephalopathy was present in 
21% of patients. Ascites was absent in 67%, 30% had 
a mild to moderate degree, and 3% had severe ascites. 
The median (IQR) MELD score was 15 (12-18), and the 
proportion with Child Pugh Score A, B, and C was 19%, 
60%, and 21%, respectively. 
Characteristics associated with beta-blocker use
Out of the 344 patients, 181 (53%) were taking a beta-
blocker at the time of assessment: 68% were taking 
propranolol, 15% nadolol, and 17% other beta-blockers 
(Supplemental Table 1). 
Baseline characteristics of beta-blocker users vs non-
users are shown in Table 1, columns B and C, respectively. 
The two groups were similar with respect to age, race/
ethnicity, etiology of liver disease, degree of ascites, rates 
of hepatic encephalopathy, MELD scores and Child Pugh 
scores. Beta-blocker users vs non-users had a lower 
percentage of females (25% vs 46%; P < 0.001), higher 
body mass index (29.3 kg/m2 vs 27.7 kg/m2; P = 0.008), 
and higher rates of HCC (32% vs 22%; P = 0.04). 
Median (IQR) heart rate (in beats per minute) 
differed significantly between beta-blocker users and 
non-users [67 (61-74) vs 76 (69-85); P < 0.001]. 
There was no significant difference in systolic or diastolic 
blood pressure between the two groups.
Associations between beta-blocker use and physical 
frailty
A comparison of characteristics by beta-blocker use is 
presented in Table 2. Median LFI was statistically, but 
not clinically, significantly worse in beta-blocker users 
compared to non-users (3.75 vs 3.64; P = 0.04). 
Rates of frailty were similar between the two groups 
(14% vs 14%), but there was a trend toward a lower 
rate of patients who were classified as robust among 
beta-blocker users vs non-users (16% vs 25%; P = 
0.06). There was no difference in rates of self-reported 
exhaustion or physical activity between the two groups 
(Table 2).
In univariable logistic regression, beta-blocker use 
was not significantly associated with physical frailty as 
defined by LFI ≥ 4.5 [OR 0.99 (95%CI: 0.54-1.83)], 
exhaustion [OR 0.97 (95%CI: 0.63-1.48)], or low 
physical activity [OR 0.92 (95%CI: 0.60-1.41)]. The 
associations between beta-blocker use and physical frailty 
by LFI ≥ 4.5 [OR 0.97 (95%CI: 0.50-1.87)], exhaustion 
[OR 0.97 (95%CI: 0.63-1.50)], or low physical activity 
[OR 1.18 (95%CI: 0.74-1.89)] did not change after 
multivariable adjustment. There was no association 
between physical frailty and each unit increase in dosing 
of either propranolol [OR 1.00 (95%CI: 0.98-1.02)] or 
nadolol [OR 0.99 (95%CI: 0.92-1.08)]. 
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(33% vs 22%; P = 0.02).
In univariable competing risks regression, beta-
blocker use was significantly associated with decreased 
mortality, whereas creatinine, HE and LFI score were 
significantly associated with increased waitlist mortality 
(Table 3). After adjustment for all independent predictors, 
beta-blocker use remained associated with decreased 
hazard of waitlist mortality [SHR 0.55 (95%CI 0.36-0.83) 
Beta-blocker use and wait-list mortality
Median (IQR) follow-up time was 12 (4-22) mo. By 
the end of follow-up, 92 (27%) patients died or were 
delisted for being too sick, 167 (48%) underwent liver 
transplant, 47 (14%) were delisted for other reasons, 
and 37 (11%) remained on the waitlist. Patients who 
were not beta-blocker users vs beta-blocker users had 
a higher proportion who died/delisted for being too sick 
Table 1  Patient demographics
Characteristics All On beta blockers Not on beta blockers P  value
n  = 344 n  = 181 (53%) n  = 163 (47%)
Age (yr) 60 (54-64) 61 (54-65) 60 (54-63) 0.16
Female 35% 25% 46% < 0.001
Race/ethnicity 0.26
   Non-Hispanic White 57% 56% 58%
   Black 4% 3% 6%
   Hispanic White 27% 30% 23%
   Asian 7% 5% 8%
   Other 6% 7% 5%
Etiology of liver disease 0.39
   Hepatitis C 50% 51% 49%
   Alcohol 15% 15% 15%
   Nonalcoholic steatohepatitis 13% 15% 11%
   Autoimmune/cholestatic 11% 9% 14%
   Hepatitis B 4% 2% 6%
   Other 6% 7% 6%
HCC 27% 32% 22% 0.04
BMI (kg/m2) 28.4 (24.9-33.0) 29.3 (25.8-33.7) 27.7 (24.2-31.8) 0.0081
Medical co-morbidities
   Hypertension 44% 48% 40% 0.12
   Diabetes 32% 36% 27% 0.06
   Coronary artery disease 7% 10% 4% 0.04
Lab tests
   Lab MELD 15 (12-18) 15 (13-18) 15 (12-18) 0.55
   Total bilirubin (mg/dL) 2.3 (1.6-3.4) 2.3 (1.5-3.2) 2.4 (1.7-3.6) 0.41
   INR 1.4 (1.2-1.6) 1.4 (1.3-1.6) 1.4 (1.2-1.6) 0.54
   Creatinine (mg/dL) 0.9 (0.8-1.2) 1 (0.8-1.2) 0.9 (0.7-1.2) 0.0034
   Sodium (mEq/L) 137 (134-139) 137 (135-139) 137 (134-139) 0.75
Ascites
   Mild-moderate 30% 30% 30% 0.40
   Refractory 3% 4% 2%
Hepatic encephalopathy1 21% 22% 21% 0.86
Child Pugh Score 0.89
   A 19% 18% 20%
   B 60% 60% 59%
   C 21% 22% 21%
1Defined as a Numbers Connection test > 60 s. HCC: Hepatocellular carcinoma; BMI: Body mass index; MELD: Model for End Stage Liver Disease. 
Table 2  Comparison of metrics of physical frailty by beta-blocker use
Outcome On beta blockers Not on beta blockers P  value
n  = 181 (53%) n  = 163 (47%)
Liver frailty index1 3.75 (3.37-4.15) 3.64 (3.23-4.04) 0.04
   Chair stands (s) 12.5 (10-16.2) 10.9 (8.3-13.2) 0.003
   Grip strength (kg) 33.3 (24.3-40) 29 (22-37) 0.03
   Balance (s) 30 (30-30) 30 (26.6-30) 0.20
LFI Frail 14% 14% 0.98
LFI Robust 16% 25% 0.06
Exhaustion 51% 52% 0.89
MNLTPA frailty 58% 60% 0.69
1Five missing data points. LFI: Liver frailty index; MNLTPA: Minnesota leisure time physical activity scale. 
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P = 0.005].
DISCUSSION
Non-selective beta-blockers have become a cornerstone 
of medical management for patients with cirrhosis to 
reduce the risk of variceal hemorrhage and have been 
associated with mortality benefit[9,12,13]. However, beta-
blockers also have a number of well-known side effects, 
including fatigue and weakness, which may be particularly 
challenging for patients with cirrhosis who already 
experience a high burden of fatigue and weakness from 
their cirrhosis, in addition to polypharmacy[14]. These 
common side effects of non-selective beta-blockers could, 
in turn, theoretically accelerate physical frailty, a potent 
determinant of mortality in this population[1-3].
In this study, we demonstrated that the addition of a 
beta-blocker is not associated with clinically-significantly 
increased rates of physical frailty or its associated 
symptoms of exhaustion or low physical activity. While 
patients on non-selective beta-blockers had statistically 
worse LFI scores than patients not on non-selective beta-
blockers, the difference in the median values for each 
group was 0.11, which does not meet the 0.2 threshold 
for the minimum clinically important difference in LFI[15]. 
This is supported by the fact that rates of physical 
frailty, using the LFI cut-off of ≥ 4.5[1], were similar 
between the two groups. Furthermore, our analyses 
confirmed the known overall mortality benefits of beta-
blocker therapy[9,12,13]. The fact that the vast majority 
of our cohort did not have refractory ascites supports 
the concept of a “therapeutic window” for benefit of 
beta-blockers on mortality in patients with cirrhosis[7]. 
Importantly, our data add to the existing body of 
literature by adjusting for the differences in frailty, which 
is now established to be an important determinant of 
mortality in patients with end-stage liver disease[1]. 
We acknowledge several limitations to our study. 
Since this was a cross-sectional study, we were only 
able to ascertain beta-blocker use at a single visit, but 
recognize that beta-blocker prescription could have 
changed during the course of the patient’s time on the 
waitlist. Adherence to beta-blocker therapy could not be 
verified, but the median heart rate was significantly lower 
in the beta-blocker users. Inclusion of only outpatients 
with MELD scores ≥ 12 limits the study’s generalizability 
to the liver transplant population as a whole, but we 
expect those with MELD scores < 12 to be less frail and 
therefore, even less affected by beta-blocker use. Lastly, 
given the observational nature of this study, we could not 
conclude the absence of causality between non-selective 
beta-blockers and physical frailty.
Despite these limitations, our data provide impor-
tant data for clinicians who manage patients with 
cirrhosis and portal hypertension. This study is, to 
our knowledge, the first to investigate the association 
between commonly reported beta-blocker side effects 
of fatigue and weakness on physical frailty, of which 
fatigue and weakness are major components. The lack 
of any clinically meaningful difference in rates of physical 
frailty in addition to the strong association with mortality 
benefit of non-selective beta-blockers (in this study and 
in others[9,12,13]) provide reassuring evidence in support of 
non-selective beta-blocker use when indicated. 
ARTICLE HIGHLIGHTS
Research background
Patients with cirrhosis are vulnerable to developing physical frailty, and it is 
becoming increasingly apparent that frailty predicts poor waitlist mortality. 
Frequently reported side effects of beta-blockers include weakness and fatigue, 
which overlap with aspects of frailty. 
Research motivation
There are an increasing number of studies that indicate physical frailty as 
a predictor of mortality in patients awaiting liver transplant. Given that beta-
blockers have commonly reported side effects of fatigue and weakness, it is 
possible that they could accelerate physical frailty. 
Research objectives
The objective of this study was to determine the association between beta-
blocker use with physical frailty, exhaustion, physical activity and mortality in 
patients with cirrhosis.
Research methods
Three-hundred-forty-four patients with cirrhosis underwent physical frailty 
testing using the Liver Frailty Index, which includes chair stands, grip strength 
and balance testing. Data was also collected on self-reported assessments 
of exhaustion and amount of physical activity. Data on beta-blocker usage 
was obtained from chart review. Both univariable and multivariable logistic 
regression were performed to determine if there was an association with 
Table 3  Competing risks survival analysis
Variable Univariable SHR 
(95%CI)
Multivariable SHR 
(95%CI)
P  value P  value
Being on a Beta Blocker 0.57 (0.38-0.85) 0.55 (0.36-0.83)
0.006 0.005
Liver Frailty Index 1.52 (1.13-2.03) 1.35 (1.02-1.80)
0.005 0.04
MELD score 1.03 (0.99-1.07)
0.19
Creatinine 1.17 (1.07-1.28) 1.10 (1.00-1.22)
0.001 0.006
Albumin 0.79 (0.56-1.12)
0.18
Sodium 0.99 (0.95-1.04)
0.76
HCC 0.80 (0.50-1.29)
0.37
Ascites 0.98 (0.63-1.51)
   0.92
Age 1.02 (0.99-1.04)
0.15
Gender (female) 1.09 (0.72-1.65)
0.68
Hepatic encephalopathy 1.99 (1.30-3.05) 1.64 (1.05-2.57)
(> 60 s) 0.001 0.03
HCC: Hepatocellular carcinoma; MELD: Model for End Stage Liver 
Disease; SHR: subdistribution hazard ratio.
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physical frailty and beta-blocker use. 
Research results
Fifty three percent of the patients were prescribed a beta-blocker. In both 
univariable and multivariable models, beta-blocker users did not have increased 
odds of physical frailty (as defined by LFI ≥ 4.5), higher rates of exhaustion, or 
lower physical activity levels. Patients on beta-blockers had a 45% reduction in 
odds of waitlist mortality compared to patients not on beta-blockers.
Research conclusions
Our study demonstrates that in patients with cirrhosis, beta-blocker use is 
not associated with physical frailty, exhaustion, or lower physical activity. 
Furthermore, our study confirms the survival benefits of beta-blocker use. 
Research perspectives
Taken together, our findings suggest that there is no association with beta-
blocker use and physical frailty, and that concerns about side effects should not 
prevent their use when indicated. Since this is an observational study, future 
studies will be needed to conclude the absence of causality. 
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